SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

blonca9
Jan 14
1 min read

Updated: Apr 22

Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis, Prader-Willi, and essential tremor. Plus, the company's $700M cash balance and deal appetite.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight